SkyWest, Inc. Declares 79th Consecutive Quarterly Dividend
Get Alerts SKYW Hot Sheet
Join SI Premium – FREE
ST. GEORGE, Utah, March 16, 2015 /PRNewswire/ -- The Board of Directors of SkyWest, Inc. (NASDAQ: SKYW) declared a quarterly dividend of $.04 per share to Shareholders of record at the close of business on March 31, 2015 on all shares then issued and outstanding. The 79th consecutive dividend will be paid on April 6, 2015.
About SkyWest
SkyWest is the holding company for two scheduled passenger airline operations and an aircraft leasing company, and is headquartered in St. George, Utah. SkyWest's scheduled passenger airline operations consist of SkyWest Airlines, Inc. ("SkyWest Airlines"), also based in St. George, Utah, and ExpressJet Airlines, Inc. ("ExpressJet Airlines"), based in Atlanta, Georgia. SkyWest Airlines operates as United Express, Delta Connection, American Eagle and US Airways Express carriers under contractual agreements with United Airlines, Inc. ("United"), Delta Air Lines, Inc. ("Delta"), American Airlines, Inc. ("American") and US Airways, Inc., respectively. SkyWest Airlines also operates flights for Alaska Airlines under a contractual agreement. ExpressJet Airlines operates as United Express, Delta Connection, and American Eagle carriers under contractual agreements with United, Delta and American, respectively. System-wide, SkyWest serves markets in the United States, Canada, Mexico and the Caribbean with approximately 3,300 daily departures and a fleet of approximately 751 regional aircraft. This press release and additional information regarding SkyWest can be accessed at www.skywest.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/skywest-inc-declares-79th-consecutive-quarterly-dividend-300051285.html
SOURCE SkyWest, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
- Frontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026
- New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share